Literature DB >> 22035911

[The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma].

C Perrin1, J-J Patard, F Jouan, N Collet, S Théoleyre, J Edeline, S Zerrouki, B Laguerre, M-A Bellaud-Roturaud, N Rioux-Leclercq, C Vigneau.   

Abstract

OBJECTIVE: To determine the prognostic significance of the neutrophil gelatinase-associated lipocalin (NGAL) and the matrix metalloproteinase 9 (MMP-9) in clear cell renal cell carcinoma (CCRCC). PATIENTS AND METHODS: NGAL and MMP-9 expression were quantified by immunohistochemistry in clear renal cell carcinoma tissues and in sera by Enzyme Linked Immunosorbent Assay (Elisa). Results were associated with clinicopathologic data.
RESULTS: Seventy-four patients operated for CCRCC in Rennes between 2003 and 2009 were included. High concentrations of NGAL-MMP-9 complex in serum were associated with short progression free survival (PFS) (33.3 months versus 47.3 months, P=0.016) and poor overall survival (42.5 months versus 51.9 months, P<0.047). High NGAL concentrations in serum were also associated with shorter PFS (13.6 months versus 41.6 months, P=0.04). However, no NGAL expression was observed in renal tumor cells. Interestingly, NGAL was expressed by neutrophils infiltrating CCRCC and we showed that the density of NGAL expressing neutrophils was associated with pejorative PFS and survival (36.9months versus 56.1 months, P<0.006).
CONCLUSION: In this study, we showed the pejorative significance of NGAL-MMP-9 complex and NGAL rates in serum of CCRCC. We also confirmed that density of NGAL expressing neutrophils in CCRCC was associated with poor outcome. Copyright Â
© 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22035911     DOI: 10.1016/j.purol.2011.06.005

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  7 in total

Review 1.  Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?

Authors:  Michael Garcia-Roig; Nicolas Ortiz; Vinata Lokeshwar
Journal:  Curr Urol Rep       Date:  2014-01       Impact factor: 3.092

2.  MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer.

Authors:  Sukhwinder Kaur; Neil Sharma; Shiv Ram Krishn; Imay Lakshmanan; Satyanarayana Rachagani; Michael J Baine; Lynette M Smith; Subodh M Lele; Aaron R Sasson; Sushovan Guha; Kavita Mallya; Judy M Anderson; Michael A Hollingsworth; Surinder K Batra
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

3.  ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results).

Authors:  Hajer Ben Khadhra; Françoise Rose-Robert; Yves Edouard Herpe; Henri Sevestre; Gabriel Choukroun; Luc Catherine; Carole Amant; Fabien Saint
Journal:  Int Urol Nephrol       Date:  2020-08-12       Impact factor: 2.370

4.  PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

Authors:  Jianfeng Wang; Chen Wang; Pan Xu; Xiao Li; Yongning Lu; Di Jin; Xiaomao Yin; Hao Jiang; Jing Huang; Huan Xiong; Fei Ye; Jia Jin; Yu Chen; Yiqian Xie; Zhifeng Chen; Hong Ding; Hao Zhang; Rongfeng Liu; Hualiang Jiang; Kaixian Chen; Zhiyi Yao; Cheng Luo; Yiran Huang; Yuanyuan Zhang; Jin Zhang
Journal:  Theranostics       Date:  2021-03-12       Impact factor: 11.556

Review 5.  Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma.

Authors:  Kai Che; Wenkai Han; Mingxin Zhang; Haitao Niu
Journal:  Oncol Lett       Date:  2020-12-24       Impact factor: 2.967

6.  Renal neutrophil gelatinase associated lipocalin expression in lipopolysaccharide-induced acute kidney injury in the rat.

Authors:  Mei Han; Ying Li; Maodong Liu; Yingmin Li; Bin Cong
Journal:  BMC Nephrol       Date:  2012-06-27       Impact factor: 2.388

7.  Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors.

Authors:  Angelina DI Carlo
Journal:  Oncol Lett       Date:  2013-03-13       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.